Navigation Links
Insulet Reports First Quarter 2008 Results
Date:5/13/2008

1,200 New Patients Shipped in the Quarter

Production Increases to 95,000 OmniPods per Month

Salesforce Expands to Cover All 50 States

BEDFORD, Mass., May 13 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD), a leader in wearable insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the first quarter ended March 31, 2008.

First quarter 2008 reported revenue increased 232% to $6.7 million compared to $2.0 million in the first quarter of 2007. On a sequential basis, reported revenue rose 53% from $4.4 million in the fourth quarter of 2007. During the first three months of 2008, approximately 1,200 new patients began using the OmniPod System.

Reported revenue for the first quarter of 2008 was favorably impacted by $1.2 million due to a change in the Company's estimate of deferred revenue. Prior to the first quarter of 2008, the Company deferred revenue on all initial shipments from the final 45 days in the quarter. The Company's deferred revenue is now based on its two years of historical experience.

Net loss for the first quarter of 2008 was $19.9 million, or $0.73 per share, compared to a net loss of $11.6 million or $23.86 per share for the first quarter of 2007. Total operating expenses increased to $16.7 million in the first quarter of 2008 compared to $8.2 million in the first quarter of 2007 and $13.7 million in the fourth quarter of 2007. Most of the increase in operating expenses was related to higher sales and marketing expenses as the Company's commercial expansion continues.

"We are pleased that we delivered another strong quarter as we continued to launch OmniPod across the United Sta
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
2. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2010 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix for ... today reported financial results for the third quarter ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO ...
... N.J., Nov. 4, 2010 PharmaNet Development Group, Inc., ... pharmaceutical, biotechnology, generic drug and medical device companies, today ... by Company scientists at the 2010 American Association of ... from November 14 -18 at the Ernest N. Morial ...
... seventeen Texas biotechnology companies were awarded more than $35 ... part of the Qualifying Therapeutic Discovery Project Tax Credit ... and the National Institutes of Health. "The ... the ability to continue to invest resources into their ...
Cached Biology Technology:Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 7PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 2PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 3Texas Biotech Firms Receive More Than $35 Million in Federal Grants and Credits 2Texas Biotech Firms Receive More Than $35 Million in Federal Grants and Credits 3
(Date:4/15/2014)... nanoparticle form could help reduce side effects by targeting ... scientists have developed nanoparticles that deliver one or two ... design particles that can carry any more than that ... devised a new way to build such nanoparticles, making ... drugs. In a paper published in the Journal ...
(Date:4/15/2014)... temperatures in the Congo Basin to increase by ... by greenhouse gases by half, according to a ... Belgium. , Explosive population growth and inefficient agricultural ... in Central Africa. A team of researchers from ... will affect longer-term temperatures in the region. Using ...
(Date:4/15/2014)... systems soon could be powering the forklifts used in ... with faster refueling times than ever before, courtesy of ... Carriers (HHC). , The goal of the project is ... refuel at low pressure four to five times faster ... hydrogen a competitive advantage over batteries for a big ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Study: Deforestation could intensify climate change in Congo Basin by half 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4
... intelligent prey such as monkeys which have exceptionally large ... The study, carried out by Dr Susanne Shultz, from ... Africa and South America such as the jaguar, chimpanzee, ... a small brain such as small antelope, mongooses and ...
... report that tumor cells display a dramatic reduction of ... to activate the expression of protective microRNAs in the ... issue of Cancer Cell, demonstrates that agents known to ... may function as tumor suppressors in normal cells and ...
... 90 years that cancer cells commonly display altered ... is not completely understood. Now, a new study ... reveals a functional connection between carbohydrate-driven energy production ... inhibition of a specific aspect of glucose metabolism ...
Cached Biology News:Activation of microRNA inhibits cancer gene in human cancer cells 2Researchers attack tumor cells by exploiting dependency on sugar metabolism 2
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: